Anis Fahandej-Sadi’s Post

TLDR Biotech for June 20 - 23 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 & 𝐋𝐚𝐛𝐞𝐥𝐬: Bristol Myers Squibb lands FDA ok for colorectal cancer treatment 🎉 + 7 more stories 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Melodia Therapeutics acquires pre-clinical cathepsin C inhibitor from Alivexis 💼 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Eli Lilly presents positive Ph3 data for GIP/GLP-1 in sleep apnea 💤 + 1 more story 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Rapafusyn Pharmaceuticals raises $28M Series A 💰 + 1 more story 𝐈𝐏𝐎𝐬: Tectonic Therapeutics debuts on NASDAQ via reverse merger with AVROBIO 📈 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Biocon seeks partner for testing Ozempic generics in China 🤝 + 1 more story 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐀𝐜𝐜𝐞𝐬𝐬: Vertex and NHS reach reimbursement deal for cystic fibrosis treatments 🏥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: Study shows AI can accelerate clinical trial enrolments 🤖 𝐋𝐚𝐲𝐨𝐟𝐟𝐬: Ginkgo Bioworks cuts 158 staff, with more expected 😟 + 1 more story All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gKDcuBXa Or subscribe to get it straight to your inbox: https://lnkd.in/gecXctqM #tldrbiotech #biotechnews #pharmanews

The global #CAR #T-#Cell #Therapy #Market is projected to skyrocket to over 𝐔𝐒𝐃 𝟐𝟐.𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, up from 𝐔𝐒𝐃 𝟐.𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑. This represents an impressive #CAGR of 30% from 2024 to 2032. This remarkable growth highlights the increasing importance of innovative cancer treatments. 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐭𝐨 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐯𝐢𝐬𝐢𝐭:- https://lnkd.in/gZmTCPCm 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 Novartis bluebird bio. Cellectis Bristol Myers Squibb Merck. Juno Therapeutics, Inc. Celyad Oncology Celgene Sorrento Therapeutics, Inc. Miltenyi Biotec Intellia Therapeutics, Inc. Pfizer, Inc. Autolus Therapeutics Gilead Sciences, Cartesian Therapeutics, Caribou Biosciences, Inc. Other Prominent Players #CARTCellTherapy #Biotech #HealthcareInnovation #MarketGrowth #CancerTreatment

Great to see our recent positive FDA feedback regarding #bexmarilimab featured in the Daily Mail!   This is further recognition of the promising potential of our wholly-owned immunotherapy asset and highlights our commitment of advancing promising new cancer treatments to a broader patient population as early as possible.   Read the article here: https://lnkd.in/ePyZf935   #Faron #biotech #drugdevelopment

🧬 𝐂𝐀𝐑𝐬 𝐯𝐬 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐬 The field of oncology and blood cancers is evolving, and thankfully, patients are benefiting from an increasing number of therapeutic options. This meta-analysis compares studies on two innovative therapies—CAR T-cells and bispecific antibodies. Among the studies, which involved over 1,000 patients in total, CAR T-cell therapy showed higher complete remission and progression-free survival rates compared to bispecific antibodies. However, CAR T-cell therapy remains less accessible due to manufacturing or regulatory constraints. 𝘏𝘰𝘸 𝘤𝘢𝘯 𝘸𝘦 𝘰𝘷𝘦𝘳𝘤𝘰𝘮𝘦 𝘵𝘩𝘦𝘴𝘦 𝘰𝘣𝘴𝘵𝘢𝘤𝘭𝘦𝘴 𝘵𝘰 𝘮𝘢𝘬𝘦 𝘊𝘈𝘙 𝘛-𝘤𝘦𝘭𝘭 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘢𝘯𝘥 𝘰𝘵𝘩𝘦𝘳 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵𝘴 𝘮𝘰𝘳𝘦 𝘢𝘤𝘤𝘦𝘴𝘴𝘪𝘣𝘭𝘦 𝘵𝘰 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴? #cart #celltherapy #pharma #biotech #drjojo ---------- Hi! I am Joanna, and my friends call me Dr Jojo 🌸 𝐈 𝐭𝐚𝐥𝐤 𝐚𝐛𝐨𝐮𝐭 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 ♻️ Share this if you find it interesting 🔔 Follow for insights you won't want to miss

𝐂𝐚𝐧𝐝𝐢𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐰𝐢𝐭𝐡 $𝟑𝟕𝟎𝐌 𝐭𝐨 𝐋𝐞𝐚𝐝 𝐢𝐧 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Candid Therapeutics, Inc. ("Candid") Candid Therapeutics, a biotechnology company focused on developing transformative drugs for autoimmune diseases, has officially launched. With groundbreaking data showing the crucial role of B lymphocytes in autoimmune pathology, Candid is pioneering T-cell engager (TCE) antibodies to selectively deplete B cell populations. Candid aims to lead the market in TCE therapies for conditions like rheumatoid arthritis and myasthenia gravis. To accelerate development, Candid acquired Vignette Bio and TRC 2004 in a three-way merger. This acquisition brings two cutting-edge bispecific TCEs: CND106 (BCMAxCD3 bispecific antibody) and CND261 (CD20xCD3 bispecific antibody), both with potential to become best-in-class autoimmune therapies. These candidates have completed Phase 1 studies, with promising data from over 130 oncology patients. The Candid team includes Ken Song, MD (CEO) Ken Song, Timothy Lu, MD, PhD (CSO), Bernie Huyghe, PhD (CTO) Bernie Huyghe, and Arvind Kush (CFO) Arvind Kush. Candid has raised over $370 million from top-tier investors, including Venrock Healthcare Capital Partners, Fairmount, TCGX, venBio Partners, and others, underscoring confidence in its vision to advance TCE therapies for autoimmune diseases. “TCE antibodies hold the potential to revolutionize autoimmune treatments," said Ken Song, MD Ken Song, CEO of Candid Therapeutics. "We aim to surpass the success of therapies like Humira® and Rituxan®, creating a new paradigm for autoimmune disease treatment.” #Biotechnology #AutoimmuneDisease #CellTherapy #TCEAntibodies #LifeSciences #PharmaInnovation #Healthcare #Biopharma #MedicalResearch #GeneticMedicine

We are pleased to have Spexis AG during our London lunch event. Spexis, a Swiss clinical-stage biopharmaceutical company, specializes in rare diseases and cancer. Its lead candidate, ColiFin®, an inhaled therapy for cystic fibrosis, is approved in Europe and advancing to global pivotal Phase 3 studies in early 2023. Leveraging over 25 years and $400 million of research, Spexis aims to deliver transformative therapies while seeking strategic partnerships for product development and market expansion. Additionally, it expands its portfolio through in-licensing or acquisitions, targeting areas with significant unmet medical needs. The Global Rare Disease Treatment Market size was valued at $152bn in 2023 and is poised to grow at a CAGR of 12.8% to reach $400bn by 2031. Our Family is looking closely at their strategy to take a view on this opportunity.   #UCEACapital #investing #familyoffices #London #SPEXIS #Healthcare #oncology #biotech 

T-Cell Engagers: From Oncology to Autoimmune T-cell #engagers (TCEs), renowned for their success in #cancer therapy, are now gaining traction as a novel approach to treating #autoimmune diseases. While the use of #bispecifics for autoimmune indications is more advanced, the application of TCEs in this space marks an exciting frontier. The Challenge: Traditional treatments like #corticosteroids and alkylating agents often come with significant side effects and inconsistent #efficacy. Even targeted #therapies, such as #rituximab, can result in broad B-cell depletion due to the widespread expression of CD20. The Opportunity: TCEs offer a more targeted strategy, leveraging their unique mechanism to selectively eliminate #pathogenic #immune cells. Some Key Innovators: 🔸 Xencor & Janssen – Plamotamab (Phase 2) 🔸 IGM Biosciences, Inc. – Imvotamab (Phase 1/2) 🔸 Cullinan Therapeutics – CLN-978 (Phase 1) 🔸 Roche – RO7507062 (Phase 1) 🔸 EvolveImmune Therapeutics – EVOLVE205 (Preclinical) 🔸 Xencor – XmAb657 (Preclinical) Recent Deals Highlighting Industry Momentum: 🔹 Leads Biolabs & Oblenio Bio (Nov 7, 2024) – USD 614M potential deal value 🔹 GSK & Chimagen Biosciences (Oct 29, 2024) – USD 850M potential deal value 🔹 Merck & Co & Curon Biopharmaceutical (Aug 9, 2024) – USD 1.3B potential deal value 🔹 Genor & TRC 2004 (Aug 5, 2024) – USD 443M + royalties With significant partnerships forming, excited to see how TCEs will transform the treatment landscape for autoimmune diseases. #TCellEngagers #AutoimmuneDiseases #Immunotherapy #BiotechInnovation #Partnerships #MoA

𝗧𝗵𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗡𝗲𝘄𝘀 𝟮𝟬𝟮𝟰 Decoding the News: Key Insights from the News Article ⬇ Below are the links to the respective news articles: 1. Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it. https://lnkd.in/gd3WcRSm 2. Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short. https://lnkd.in/gyNnm4CK 3. Takeda drug for rare types of epilepsy misses goal in late-stage trial https://lnkd.in/gaQeYwrh 4. Decheng Capital Eyes $700M Raise for Fifth Life Sciences Fund as VC Heats Up. https://lnkd.in/gYVaShHK 5. Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group. https://lnkd.in/gEMx2Ejb      P.S. Comment below with the latest pharma/biotech news you came across. #pharma #cdmo #biotech

Latest Life Science News / Updates 👇 📌 TORL BioTherapeutics, LLC is the latest biotech to benefit from the ADC boom, bringing in $158 million in a B2 financing round. ➡ Asher Biotherapeutics has closed a $55 million series C to support the mission of developing therapies for cancer, autoimmune and infectious diseases. ◾ Canaan Partners adds $100m for Biotech investments plus brings in Uwe Schoenbeck to the team from Pfizer. 📌 Pathios Therapeutics drew in $25 million for the first close of a Series B raise that should help the UK biotech test its first-in-class solid tumor candidate in clinical trials by the end of the year. ◾ Alvotech and Teva Pharmaceuticals have announced approval from the FDA for Selarsdi via subcutaneous injection. ➡ Scopio Labs receives groundbreaking FDA Clearance for first-ever Digital Bone Marrow Aspirate application 📌 Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer ◾ Sensorium Therapeutics appoints Sam Rasty as Chief Business Officer

Thoughts on this? >> Candel’s promising Phase 2 data in pancreatic cancer; Microbiome biotech raises £27M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #healthcare #pharma #biotech